IRIX vs. SCYX, NSPR, SRTS, JATT, IMRX, HSAQ, AMIX, DYAI, ZEPP, and FIXX
Should you be buying IRIDEX stock or one of its competitors? The main competitors of IRIDEX include SCYNEXIS (SCYX), InspireMD (NSPR), Sensus Healthcare (SRTS), JATT Acquisition (JATT), Immuneering (IMRX), Health Sciences Acquisitions Co. 2 (HSAQ), Autonomix Medical (AMIX), Dyadic International (DYAI), Zepp Health (ZEPP), and Homology Medicines (FIXX).
IRIDEX (NASDAQ:IRIX) and SCYNEXIS (NASDAQ:SCYX) are both small-cap computer and technology companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, community ranking, earnings, media sentiment, dividends, risk and analyst recommendations.
SCYNEXIS received 233 more outperform votes than IRIDEX when rated by MarketBeat users. Likewise, 70.24% of users gave SCYNEXIS an outperform vote while only 70.10% of users gave IRIDEX an outperform vote.
20.1% of IRIDEX shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 6.2% of IRIDEX shares are owned by company insiders. Comparatively, 4.4% of SCYNEXIS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, IRIDEX and IRIDEX both had 2 articles in the media. IRIDEX's average media sentiment score of 0.59 beat SCYNEXIS's score of 0.53 indicating that IRIDEX is being referred to more favorably in the media.
SCYNEXIS has higher revenue and earnings than IRIDEX. IRIDEX is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.
IRIDEX currently has a consensus target price of $2.00, indicating a potential downside of 31.97%. SCYNEXIS has a consensus target price of $15.00, indicating a potential upside of 900.00%. Given SCYNEXIS's higher probable upside, analysts plainly believe SCYNEXIS is more favorable than IRIDEX.
SCYNEXIS has a net margin of 47.84% compared to IRIDEX's net margin of -18.45%. SCYNEXIS's return on equity of 156.27% beat IRIDEX's return on equity.
IRIDEX has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500.
Summary
SCYNEXIS beats IRIDEX on 13 of the 16 factors compared between the two stocks.
Get IRIDEX News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IRIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
